Search clinical trials for: Vaxigripetra

Total 13 results

Chronic Obstructive Pulmonary Disease Trial Network...
The Novo Nordic Foundation

Not yet recruiting

Vaccine Pandemic Preparedness Through Airway Immunology Characterization (VAXXAIR)

Influenza, Human

United Kingdom, Denmark
LiteVax BV
University Hospital, Ghent; HarmonyCR, Melle, Belgium

Recruiting

Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine (TETRALITE-Ib)

Vaccination Reaction

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam (GQM10)

Influenza

Vietnam
Centers for Disease Control and Prevention
University of Michigan; Rabin Medical Center; Soroka University Medical Center; Abt Associates and other collaborators

Completed

Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel

Influenza

Israel
Assistance Publique - Hôpitaux de Paris
Hospices Civils de Lyon; Sanofi Pasteur, a Sanofi Company

Completed

Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients (FLUO)

Morbid Obesity | Severe Obesity

France
Sanofi

Completed

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above

Influenza

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22

Influenza (Healthy Volunteers)

Germany, Finland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine

Influenza

Mexico
Sanofi

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24

Influenza Immunization (Healthy Volunteers)

Finland, Germany
Sanofi

Completed

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months

Influenza

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

Influenza (Healthy Volunteers)

Germany, Finland
St. Petersburg Research Institute of Vaccines and...

Recruiting

Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children

Vaccine Reaction | Influenza | Influenza, Human | Influenza Viral Infections

Russian Federation
Sanofi Pasteur, a Sanofi Company

Terminated

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Finland

3

Subscribe